OQS
NKTR icon

Occudo Quantitative Strategies’s Nektar Therapeutics NKTR Stock Holding History

Occudo Quantitative Strategies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$773K Buy
11,074
+2,126
+24% +$156K 0.04% 424
2026
Q1 		$761K Buy
+8,948
New +$509K 0.04% 439
2023
Q4 		– Sell
-1,916
Closed -$17.1K – 1067
2023
Q3 		$17.1K Sell
1,916
-8,094
-81% -$77.9K ﹤0.01% 925
2023
Q2 		$86.4K Hold
10,010
– – 0.01% 938
2023
Q1 		$106K Sell
10,010
-6,398
-39% -$194K 0.01% 815
2022
Q4 		$556K Sell
16,408
-4,399
-21% -$213K 0.06% 470
2022
Q3 		$999K Buy
20,807
+1,441
+7% +$85.7K 0.08% 399
2022
Q2 		$1.1M Buy
19,366
+12,617
+187% +$796K 0.09% 354
2022
Q1 		$546K Buy
6,749
+4,560
+208% +$675K 0.05% 613
2021
Q4 		$444K Sell
2,189
-328
-13% -$71.2K 0.04% 655
2021
Q3 		$678K Buy
2,517
+1,843
+273% +$443K 0.08% 423
2021
Q2 		$174K Buy
+674
New +$187K 0.03% 737
2021
Q1 		– Sell
-1,576
Closed -$402K – 871
2020
Q4 		$402K Buy
+1,576
New +$407K 0.13% 318

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Occudo Quantitative Strategies's NKTR Position: Q2 2026 in Review

Occudo Quantitative Strategies increased its Nektar Therapeutics (NKTR) stake by 24% in Q2 2026, buying an estimated $156K and bringing the position to 11,074 shares worth $773K. The position accounts for 0.04% of the portfolio, ranked #424.

Occudo Quantitative Strategies first reported a position in NKTR in Q4 2020 and has held it in 13 quarters since. The position peaked at $1.1M in Q2 2022. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Occudo Quantitative Strategies held 11,074 shares of Nektar Therapeutics worth $773K as of Q2 2026.
  • Occudo Quantitative Strategies bought 2,126 Nektar Therapeutics shares in Q2 2026, an estimated $156K.
  • Nektar Therapeutics made up 0.04% of Occudo Quantitative Strategies's portfolio in Q2 2026, its #424 holding.
  • Occudo Quantitative Strategies first reported a position in Nektar Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Occudo Quantitative Strategies's Nektar Therapeutics position peaked at $1.1M in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.